OBJECT: Patients with traumatic brain injury (TBI) are at risk for development of thromboembolic disease. The use of chemoprophylaxis in this patient group has not fully been characterized. The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious. METHODS: In May 2009, a protocol was instituted for patients with TBI where chemoprophylaxis for thromboembolic disease (either 30 mg of Lovenox twice daily or 5000 U of heparin 3 times a day) was initiated 24 hours after an intracranial hemorrhage (ICH) was demonstrated as stable on head CT image. Two cohorts were evaluated: Cohort A included patients from May 2008 through April 2009 who had no routine administration of chemoprophylaxis, and Cohort B included patients from May 2009 through May 2010 after the protocol was instituted. The groups were compared, with the major outcomes being deep venous thrombosis (DVT), pulmonary embolism, and increase in size of ICH. RESULTS: Of the 312 patients with TBI who were seen during the study course, 236 patients met criteria for inclusion in the study: 107 patients in Cohort A and 129 patients in Cohort B. The DVT rate was 6 occurrences (5.61%) in Cohort A and 0 occurrences (0%) in Cohort B, which was a statistically significant difference (p = 0.0080). Pulmonary embolism was found in 4 patients (3.74%) in Cohort A and 1 patient (0.78%) in Cohort B, a difference that did not reach statistical significance (p = 0.18). Three instances (2.8%) in Cohort A and 1 instance (0.7%) in Cohort B of increased ICH occurred after starting anticoagulation for chemoprophylaxis; this was not statistically different (p = 0.33). CONCLUSIONS: Use of chemoprophylaxis in TBI 24 hours after stable head CT is safe and decreases the rate of DVT formation.
OBJECT: Patients with traumatic brain injury (TBI) are at risk for development of thromboembolic disease. The use of chemoprophylaxis in this patient group has not fully been characterized. The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious. METHODS: In May 2009, a protocol was instituted for patients with TBI where chemoprophylaxis for thromboembolic disease (either 30 mg of Lovenox twice daily or 5000 U of heparin 3 times a day) was initiated 24 hours after an intracranial hemorrhage (ICH) was demonstrated as stable on head CT image. Two cohorts were evaluated: Cohort A included patients from May 2008 through April 2009 who had no routine administration of chemoprophylaxis, and Cohort B included patients from May 2009 through May 2010 after the protocol was instituted. The groups were compared, with the major outcomes being deep venous thrombosis (DVT), pulmonary embolism, and increase in size of ICH. RESULTS: Of the 312 patients with TBI who were seen during the study course, 236 patients met criteria for inclusion in the study: 107 patients in Cohort A and 129 patients in Cohort B. The DVT rate was 6 occurrences (5.61%) in Cohort A and 0 occurrences (0%) in Cohort B, which was a statistically significant difference (p = 0.0080). Pulmonary embolism was found in 4 patients (3.74%) in Cohort A and 1 patient (0.78%) in Cohort B, a difference that did not reach statistical significance (p = 0.18). Three instances (2.8%) in Cohort A and 1 instance (0.7%) in Cohort B of increased ICH occurred after starting anticoagulation for chemoprophylaxis; this was not statistically different (p = 0.33). CONCLUSIONS: Use of chemoprophylaxis in TBI 24 hours after stable head CT is safe and decreases the rate of DVT formation.
Authors: Katsuhiro Nagata; Kenichiro Kumasaka; Kevin D Browne; Shengjie Li; Jesse St-Pierre; John Cognetti; Joshua Marks; Victoria E Johnson; Douglas H Smith; Jose L Pascual Journal: J Trauma Acute Care Surg Date: 2016-12 Impact factor: 3.313
Authors: Shengjie Li; Joshua A Marks; Rachel Eisenstadt; Kenichiro Kumasaka; Davoud Samadi; Victoria E Johnson; Daniel N Holena; Steven R Allen; Kevin D Browne; Douglas H Smith; Jose L Pascual Journal: J Trauma Acute Care Surg Date: 2015-07 Impact factor: 3.313
Authors: U K Bodanapally; D Dreizin; G Issa; K L Archer-Arroyo; K Sudini; T R Fleiter Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: I Arhoun El Haddad; A El Mouhib; O Hattab; M Assamti; A Mojahid; H Bkiyer; S Nasri; I Skiker; El Ouafi; B Housni Journal: Ann Med Surg (Lond) Date: 2022-05-30
Authors: Hasan M Al-Dorzi; Ghadah Al-Yami; Fatima Al-Daker; Muhannad Q Alqirnas; Moustafa S Alhamadh; Raymond Khan Journal: Ann Thorac Med Date: 2022-04-19 Impact factor: 2.535
Authors: Katsuhiro Nagata; Kevin D Browne; Yujin Suto; Kenichiro Kumasaka; John Cognetti; Victoria E Johnson; Joshua Marks; Douglas H Smith; Jose L Pascual Journal: J Trauma Acute Care Surg Date: 2017-09 Impact factor: 3.697
Authors: Navpreet K Dhillon; Yassar M Hashim; Naomi Berezin; Felix Yong; Geena Conde; Russell Mason; Eric J Ley Journal: Trauma Surg Acute Care Open Date: 2021-05-10